Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab

Friday, September 29, 2023

8:30 AM – 8:45 AM ET

Presenter(s)

Cathy Eng, MD, FACP, FASCO

Vanderbilt-Ingram Cancer Center
MD Anderson Cancer Center